Reliable detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing: Implications for surgical management

Annals of Surgery

Volumn 263, Issue 1, 2016, Pages 153-161

  Valero, Vicente ^a   Saunders, Tyler J ^b   He, Jin ^a   Weiss, Matthew J ^a   Cameron, John L ^a   Dholakia, Avani ^a   Wild, Aaron T ^a   Shin, Eun Ji ^a   Khashab, Mouen A ^a   O'Broin Lennon, Anne Marie ^a   Ali, Syed Z ^b   Laheru, Daniel ^a   Hruban, Ralph H ^a,b   Iacobuzio Donahue, Christine A ^a,b   Herman, Joseph M ^a   Wolfgang, Christopher L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Pathology ^*  (United States)

Author keywords

Cancer genetics; Fine needle aspirates; Genomics; Next generation sequencing; Pancreatic cancer

Indexed keywords

ATM PROTEIN; GENOMIC DNA; MAMMALIAN TARGET OF RAPAMYCIN; DNA;

ARTICLE; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; DILUTION; DNA EXTRACTION; DNA SEQUENCE; FEASIBILITY STUDY; FINE NEEDLE ASPIRATION BIOPSY; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INOPERABLE CANCER; LIMIT OF DETECTION; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; PANCREAS CANCER; PRIORITY JOURNAL; SIMULATION; SOMATIC MUTATION; GENETICS; GENOTYPING TECHNIQUE; MUTATION; NUCLEOTIDE SEQUENCE; PANCREATIC NEOPLASMS; PATHOLOGY; REPRODUCIBILITY;

BASE SEQUENCE; BIOPSY, FINE-NEEDLE; DNA, NEOPLASM; GENOTYPING TECHNIQUES; HUMANS; MUTATION; PANCREATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS;

EID: 84953775551     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0000000000001156     Document Type: Article

References (45)

1. SEER Research Data 1973-2011. Available at: www.seer.cancer.gov. Published 2014.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
3. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200-1210.
4. Davila JA, Chiao EY, Hasche JC, et al. Utilization and determinants of adjuvant therapy among older patients who receive curative surgery for pancreatic cancer. Pancreas. 2009;38:18-25.
5. Mayo SC, Austin DF, Sheppard BC, et al. Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis. Cancer. 2010;116:2932-2940.
6. Slidell MB, Chang DC, Cameron JL, et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol. 2008;15:165-174.
7. Mayo SC, Gilson MM, Herman JM, et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214:33-45.
8. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267-277.
9. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310:1473-1481.
10. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299:1019-1026.
11. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817-1825.
12. Hoff Von DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691-1703.
13. Young G, Wang K, He J, et al. Clinical next-generation sequencing successfully applied to fine-needle aspirations of pulmonary and pancreatic neoplasms. Cancer Cytopathol. 2013;121:688-694.
14. Iacobuzio-Donahue CA, Fu B, Yachida S, et al. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-1813.
15. Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, et al. Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther. 2011;10:3-8.
16. Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491:399-405.
17. Walter K, Omura N, Hong SM, et al. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin Cancer Res. 2010;16:1781-1789.
18. Rago C, Huso DL, Diehl F, et al. Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. Cancer Res. 2007;67:9364-9370.
19. Yachida S, White CM, Naito Y, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long-term survivors. Clin Cancer Res. 2012;18:6339-6347.
20. Deer EL, González-Hernández J, Coursen JD, et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas. 2010;39:425-435.
21. Calhoun ES. Identifying allelic loss and homozygous deletions in pancreatic cancer without matched normals using high-density single-nucleotide polymorphism arrays. Cancer Res. 2006;66:7920-7928.
22. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature. 2010;467:1114-1117.
23. Hahn SA, Schutte M, Hoque ATMS, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271:350-353.
24. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb (p16 tumorsuppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 1997;57:3126-3130.
25. Caldas C, Hahn SA, Da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet. 1994;8:27-32.
26. Iacobuzio-Donahue CA. Missense mutations of MADH4: characterization of the mutational hot spot and functional consequences in human tumors. Clin Cancer Res. 2004;10:1597-1604.
27. Herman JM, Chang DT, Goodman KA, et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015;121:1128-1137.
28. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321:1801-1806.
29. Vogelstein B, Papadopoulos N, Velculescu VE, et al. Cancer genome landscapes. Science. 2013;339:1546-1558.
30. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012;2:41-46.
31. Williams JR, Zhang Y, Zhou H, et al. Overview of radiosensitivity of human tumor cells to low-dose-rate irradiation. Int J Radiat Oncol Biol Phys. 2008;72:909-917.
32. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100, 313 patients diagnosed from 1985-1995, using the National Cancer Database11No competing interests declared. J Am Coll Surg. 1999;189:1-7.
33. Wu J, Jiao Y, Dal Molin M, et al. Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitindependent pathways. Proc Natl Acad Sci USA. 2011;108:21188-21193.
34. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. 2011;331:1199-1203.
35. Ross JS, Wang K, Al-Rohil RN, et al. Advanced urothelial carcinoma: nextgeneration sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 2013;27:271-280.
36. Crane CH, Iacobuzio-Donahue CA. Keys to personalized care in pancreatic oncology. J Clin Oncol. 2012;30:4049-4950.
37. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009;324:217.
38. Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. 2012;136:100-109.
39. Ogura T, Yamao K, Hara K, et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol. 2012;48:640-646.
40. Siddiqui AA, Kowalski TE, Shahid H, et al. False-positive EUS-guided FNA cytology for solid pancreatic lesions. Gastrointest Endosc. 2011;74:535-540.
41. Varadarajulu S, Hasan MK, Bang JY, et al. Endoscopic ultrasound-guided tissue acquisition. Dig Endosc. 2013;26:62-69.
42. Hébert-Magee S, Bae S, Varadarajulu S, et al. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis. Cytopathology. 2013;24:159-171.
43. Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3:92.
44. Wagle N, Berger MF, Davis MJ, et al. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012;2:82-93.
45. Raut CP, Grau AM, Staerkel GA, et al. Diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration in patients with presumed pancreatic cancer. J Gastrointest Surg. 2003;7:118-126; discussion 127-128.